Category: ACN Newswire

Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON Global Phase 3 NefIgArd Clinical Trial

SHANGHAI, Oct 22, 2024 – (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the “Kidney 360” magazine

More